Figure 5.

LMP400/Niraparib combination prolongs survival in a GBM mouse model with PTEN deficiency. (A) An in vivo study scheme showing a timeline for the evaluation of the LMP400 and Niraparib efficacy in a GBM mouse model. (B) H&E staining of the tumor tissues harvested from the TRP mice confirmed histopathological features of glioblastoma, such as infiltrative tumor edge (upper left, 10×, scale bar 200 μm and upper right, 20×, scale bar 100 μm) and pseudopalisading necrosis (lower left, 10×, scale bar 200 μm). High cellularity, nuclear atypia, pleomorphism, and numerous mitotic figures were also observed (lower right, 40×, scale bar 50 μm). (C) Western blot of PD markers in mouse brain tumor tissues and contralateral non-tumor counterparts. (D) Kaplan–Meier survival curves of the mice treated with vehicle or LMP400 (5 mg/kg via i.p.) or Niraparib (50 mg/kg via i.p.) or combination.